Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide
Carl E Stafstrom
Section of Pediatric Neurology, Departments of Neurology and Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
Objective: This review summarizes the treatment of Lennox-Gastaut syndrome, an intractable epileptic encephalopathy of early childhood. In particular, the review focuses on rufinamide, a recently released anticonvulsant medication with reported effectiveness in this epilepsy syndrome.
Methods: A systematic literature search (PubMed) was performed to review the existing literature pertaining to the treatment of Lennox-Gastaut syndrome as well as studies involving rufinamide as an anticonvulsant medication.
Results: The published literature to date documents a beneficial effect of rufinamide on children over 4 years old with Lennox-Gastaut syndrome. Studies indicate a significant decrease in tonic and atonic seizure frequency as well as total seizure frequency compared to placebo-treated children. Rufinamide appears to be well tolerated and a safe medication, somnolence and vomiting being the most common side effects.
Conclusions: Rufinamide is a promising adjunctive therapy for Lennox-Gastaut syndrome, an intractable childhood epilepsy. To ensure its optimal effectiveness, clinicians must be familiar with the medication’s clinical response profile and potential for adverse effects.
Keywords: pediatric, epilepsy, epileptic encephalopathy, Lennox-Gastaut syndrome, rufinamide
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Readers of this article also read:
Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities
Bagheri A, Kamalidehghan B, Haghshenas M, Azadfar P, Akbari L, Sangtarash MH, Vejdandoust F, Ahmadipour F, Meng GY, Houshmand M
Published Date: 13 May 2015
Impact of chronic obstructive pulmonary diseases on left ventricular diastolic function in hospitalized elderly patients
Huang YS, Feng YC, Zhang J, Bai L, Huang W, Li M, Sun Y
Published Date: 19 December 2014
Lampe R, Blumenstein T, Turova V, Alves-Pinto A
Published Date: 9 December 2014
Sato M, Yasuhara Y, Tanioka T, Iwasa Y, Miyake M, Yasui T, Tomotake M, Kobayashi H, Locsin RC
Published Date: 17 January 2014
Olaniyi JA, Olomu SA, Finomo SA
Published Date: 30 May 2011
Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa
Butros L, Boayue K, Mathew P
Published Date: 12 May 2011
Espandar L, Sikder S, Moshirfar M
Published Date: 6 February 2011
Pär I Johansson, Sisse R Ostrowski
Published Date: 29 June 2010
Jun Iwamoto, Yoshihiro Sato, Mitsuyoshi Uzawa, et al
Published Date: 20 April 2010
Published Date: 18 September 2009